GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allena Pharmaceuticals Inc (OTCPK:ALNAQ) » Definitions » Degree of Financial Leverage

Allena Pharmaceuticals (Allena Pharmaceuticals) Degree of Financial Leverage : 0.00 (As of Jun. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Allena Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Allena Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Jun. 2022 was 0.00. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Allena Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

ALNAQ's Degree of Financial Leverage is not ranked *
in the Biotechnology industry.
Industry Median: 0.97
* Ranked among companies with meaningful Degree of Financial Leverage only.

Allena Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Allena Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allena Pharmaceuticals Degree of Financial Leverage Chart

Allena Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Degree of Financial Leverage
Get a 7-Day Free Trial 0.97 0.35 0.75 1.62 -0.59

Allena Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.91 -0.74 -0.59 -0.90 67.50

Competitive Comparison of Allena Pharmaceuticals's Degree of Financial Leverage

For the Biotechnology subindustry, Allena Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allena Pharmaceuticals's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allena Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Allena Pharmaceuticals's Degree of Financial Leverage falls into.



Allena Pharmaceuticals Degree of Financial Leverage Calculation

Allena Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Jun. 2022 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.49 (Jun. 2022) / -0.91 (Jun. 2021) - 1 )/( -42.41 (Jun. 2022) / -42.702 (Jun. 2021) - 1 )
=-0.4615/-0.0068
=67.50***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Allena Pharmaceuticals  (OTCPK:ALNAQ) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Allena Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Allena Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Allena Pharmaceuticals (Allena Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Newton Executive Park, Suite 202, Newton, MA, USA, 02462
Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.
Executives
Louis Md Brenner officer: See Remarks RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02140
Mark J. Fitzpatrick director 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Richard D Katz officer: Chief Financial Officer 4505 EMPEROR BOULEVARD, SUITE 300, DURHAM NC 27703
Edward Wholihan officer: Chief Financial Officer C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Bessemer Venture Partners Vii L.p. 10 percent owner C/O BESSEMER VENTURE PARTNERS, 1865 PALMER AVENUE, LARCHMONT NY 10538
Hbm Biocapital Ii Lp 10 percent owner 11-15 SEATON PLACE, ST. HELIER Y9 JE4 0QH
James N Topper director, 10 percent owner 550 HAMILTON AVENUE, SUITE 100, PALO ALTO CA 94301
Fhm Vi, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Robert Alexander director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Alexey L Margolin director, officer: Chief Executive Officer C/O ALTUS PHARMACEUTICALS INC., 125 SIDNEY STREET, CAMBRIDGE MA 02139

Allena Pharmaceuticals (Allena Pharmaceuticals) Headlines

From GuruFocus

Allena Pharmaceuticals Provides Clinical and Corporate Update

By GuruFocusNews GuruFocusNews 01-04-2022